Research programme: pain therapeutics - Nektar Therapeutics

Drug Profile

Research programme: pain therapeutics - Nektar Therapeutics

Alternative Names: NKTR-174; NKTR-194; NKTR-195; NKTR-196; Sodium channel blockers - Nektar Therapeutics

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nektar Therapeutics
  • Class Drug conjugates; Opioid analgesics; Small molecules
  • Mechanism of Action NMDA receptor antagonists; Opioid kappa receptor agonists; Opioid mu receptor agonists; Opioid receptor agonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Acute pain; Visceral pain
  • No development reported Neuropathic pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Neuropathic-pain in USA (PO)
  • 02 May 2014 Preclinical trials in Acute pain in USA (PO)
  • 02 May 2014 Preclinical trials in Visceral pain in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top